Latest Articles about TEVA

Teva Pharmaceutical Industries Limited (TEVA) Ex-Dividend Date Scheduled for May 16, 2013

NASDAQ.com News — Wed, 15 May 2013 17:00:04 Z

Teva Pharmaceutical Industries Limited ( TEVA ) will begin trading ex-dividend on May 16, 2013. A cash dividend payment of $0.32 per share is scheduled to be paid on June 03, 2013. Shareholders

Teva - Alexza Sign Deal for Adasuve - Analyst Blog

Zacks Equity Research — Tue, 14 May 2013 01:06:40 Z

Teva Pharmaceutical Industries Ltd. 's ( TEVA ) subsidiary, Teva Pharmaceuticals USA, Inc., recently entered into an exclusive licensing and supply agreement with Alexza Pharmaceuticals,

X Factor: 5 Stocks Reaching Their Ex-Dividend Date on May 16

Christopher Witrak — Thu, 09 May 2013 18:00:00 Z

Many stocks will reach their ex-dividend date next Thursday, which is significant for investors as the seller of the stock on that date, not the buyer, receives the most recent dividend. A

OncoGenex Loss Lower than Expected - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 23:26:28 Z

OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported first quarter 2013 net loss per share of 46 cents, narrower than the Zacks Consensus Estimate of a loss of 68 cents and the year-ago loss

Teva Beats on Earnings, Revenues - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 21:02:01 Z

Teva Pharmaceutical Industries ( TEVA ) reported first quarter earnings of $1.12 per American Depositary Share (ADS), a couple of cents above the Zacks Consensus Estimate but 23.8% below

Benzinga Market Primer: Friday, May 3: Non-Farm Payrolls Edition

Matthew Kanterman — Fri, 03 May 2013 14:24:11 Z

Futures Lower Ahead of Non-Farm Payrolls, Lower EU Outlook U.S. equity futures traded lower in early pre-market trade ahead of the Non-Farm Payrolls report for April and following the EU

Loss Widens at Momenta - Analyst Blog

Zacks Equity Research — Thu, 02 May 2013 17:57:19 Z

Momenta Pharmaceuticals Inc. ( MNTA ) reported first quarter 2013 net loss per share of 48 cents, wider than the Zacks Consensus Estimate of a loss of 43 cents and the year-ago loss of 10

Benzinga Market Primer: Thursday, May 2

Matthew Kanterman — Thu, 02 May 2013 14:53:14 Z

Futures Higher On Central Banks U.S. equity futures rose slightly in early pre-market trade following the FOMC saying that it is prepared to increase or decrease asset purchases depending on the

Pre-Market Earnings Report for May 2, 2013 : GM, MFC, TEVA, GG, K, VRX, PCG, MMC, IP, CME, SRE, PPL

NASDAQ.com News — Thu, 02 May 2013 00:00:04 Z

The following companies are expected to report earnings prior to market open on 05/02/2013. Visit our Earnings Calendar for a full list of expected earnings releases. General Motors Company

Legendary Investors Bet Big on Boomer Biotechs

Valorie Sands — Wed, 01 May 2013 18:45:00 Z

In New York City, you can't walk into a Starbucks and feign dietary ignorance while ordering your favorite Frappuccino. The calorie cost stares back at you as clearly as the price. From Wall

Bayer Aims to Expand HealthCare Portfolio - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 22:47:51 Z

In a bid to strengthen its contraceptive portfolio Bayer ( BAYRY ) inked a deal to buy Conceptus Inc. ( CPTS ) for $31.00 per share or approximately $1.1 billion in cash. Conceptus

Orphan Drug Status for Teva/Xenon Drug - Analyst Blog

Zacks Equity Research — Sat, 27 Apr 2013 00:22:50 Z

The US Food and Drug Administration (FDA) recently granted orphan drug designation to Teva Pharmaceutical Industries Ltd ( TEVA ) and Xenon Pharmaceuticals Inc. for their pain management

Data on Teva's Milprosa - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:13:34 Z

Teva Pharmaceuticals ( TEVA ) recently announced new data from a phase III study on Milprosa (progesterone) vaginal ring which is being developed for luteal phase support in women

OncoGenex' OGX-427 Progresses - Analyst Blog

Zacks Equity Research — Sat, 13 Apr 2013 01:08:04 Z

OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of

TRO on Actavis Sale of Generic Pulmicort Respules - Analyst Blog

Zacks Equity Research — Wed, 10 Apr 2013 18:50:01 Z

Actavis, Inc. ( ACT ) recently said that the US District Court for the District of New Jersey has granted AstraZeneca 's ( AZN ) motion to issue a temporary restraining order (TRO)